[HTML][HTML] The complement receptors C3aR and C5aR are a new class of immune checkpoint receptor in cancer immunotherapy
Y Wang, H Zhang, YW He - Frontiers in immunology, 2019 - frontiersin.org
Cancer immunotherapy has made remarkable clinical advances in recent years. Antibodies
targeting the immune checkpoint receptors PD-1 and CTLA-4 and adoptive cell therapy …
targeting the immune checkpoint receptors PD-1 and CTLA-4 and adoptive cell therapy …
[HTML][HTML] The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy
Y Wang, H Zhang, YW He - Frontiers in Immunology, 2019 - ncbi.nlm.nih.gov
Cancer immunotherapy has made remarkable clinical advances in recent years. Antibodies
targeting the immune checkpoint receptors PD-1 and CTLA-4 and adoptive cell therapy …
targeting the immune checkpoint receptors PD-1 and CTLA-4 and adoptive cell therapy …
The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy.
Y Wang, H Zhang, YW He - Frontiers in Immunology, 2019 - europepmc.org
Cancer immunotherapy has made remarkable clinical advances in recent years. Antibodies
targeting the immune checkpoint receptors PD-1 and CTLA-4 and adoptive cell therapy …
targeting the immune checkpoint receptors PD-1 and CTLA-4 and adoptive cell therapy …
[引用][C] The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy
Y Wang, H Zhang, YW He - Frontiers in Immunology, 2019 - cir.nii.ac.jp
The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint
Receptor in Cancer Immunotherapy | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …
Receptor in Cancer Immunotherapy | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …
The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy
Y Wang, H Zhang, YW He - The Role of Complement in Tumors, 2020 - books.google.com
Cancer immunotherapy has made remarkable clinical advances in recent years. Antibodies
targeting the immune checkpoint receptors PD-1 and CTLA-4 and adoptive cell therapy …
targeting the immune checkpoint receptors PD-1 and CTLA-4 and adoptive cell therapy …
[HTML][HTML] The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy.
Y Wang, H Zhang, YW He - 2019 - dukespace.lib.duke.edu
Cancer immunotherapy has made remarkable clinical advances in recent years. Antibodies
targeting the immune checkpoint receptors PD-1 and CTLA-4 and adoptive cell therapy …
targeting the immune checkpoint receptors PD-1 and CTLA-4 and adoptive cell therapy …
The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy
Y Wang, H Zhang, YW He - Frontiers in immunology, 2019 - pubmed.ncbi.nlm.nih.gov
Cancer immunotherapy has made remarkable clinical advances in recent years. Antibodies
targeting the immune checkpoint receptors PD-1 and CTLA-4 and adoptive cell therapy …
targeting the immune checkpoint receptors PD-1 and CTLA-4 and adoptive cell therapy …
The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy.
Y Wang, H Zhang, YW He - Frontiers in Immunology, 2019 - europepmc.org
Cancer immunotherapy has made remarkable clinical advances in recent years. Antibodies
targeting the immune checkpoint receptors PD-1 and CTLA-4 and adoptive cell therapy …
targeting the immune checkpoint receptors PD-1 and CTLA-4 and adoptive cell therapy …
[PDF][PDF] The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy
Y Wang, H Zhang, YW He - Front. Immunol. 10: 1574. doi …, 2019 - dukespace.lib.duke.edu
Cancer immunotherapy has made remarkable clinical advances in recent years. Antibodies
targeting the immune checkpoint receptors PD-1 and CTLA-4 and adoptive cell therapy …
targeting the immune checkpoint receptors PD-1 and CTLA-4 and adoptive cell therapy …